chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-FEB-2022, at 19:03; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-FEB-2022, at 19:03; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-FEB-2022, at 19:03) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-FEB-2022, at 19:03) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066h21a) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2022 at 7:03 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 12-Feb-2022 at 7:03 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-FEB-2022, at 19:03). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-FEB-2022, at 19:03). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-FEB-2022, at 19:03) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-FEB-2022, at 19:03) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant product reported by reporter. Vaccine went into 2 to 8 degrees Celsius in thaw state on or about 24 Dec 2021. Patient received booster dose. Patient ethnicity reported. The patient received Moderna vaccine past its 30 day of expiry date. Vaccine went into 2-to-8-degree Celsius thaw state on or about 24-Dec-2021. This vaccine was administered up until its manufacturing expiry date of 04-Apr-2022. We no longer possess this lot number. No treatment information was provided.
16 year old who received Moderna; This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old who received Moderna) in a 16-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old who received Moderna). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old who received Moderna) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant drug was not reported. Treatment medication was not reported.   Most recent FOLLOW-UP information incorporated above includes: On 09-Jun-2021: Follow-up information contains Vaccine facility  information, adverse event On 23-Jul-2021: Follow up information contains no Adverse reaction have been  reported by patient.
Local reaction of erythema, induration, tendernss of approx. 6 cm. fatigued.
dose of Havrix/ nonviable after a temperature excursion.; This case was reported by a physician via call center representative and described the occurrence of incorrect product storage in a 18-year-old female patient who received HAV (Havrix) (batch number 7HJ74, expiry date 21st August 2022) for prophylaxis.   On 25th June 2021, the patient received Havrix. On an unknown date, unknown after receiving Havrix, the patient experienced incorrect product storage. On an unknown date, the outcome of the incorrect product storage was unknown.  Additional details were reported as follows: A physician reported that a female patient was given a dose of Havrix on 25th June 2021 that was deemed nonviable after a temperature excursion. No symptoms were reported. The reporter consented to follow up. This case is one of 6 cases, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021142812:Same reporter US-GLAXOSMITHKLINE-US2021142816:Same reporter US-GLAXOSMITHKLINE-US2021142817:Same reporter US-GLAXOSMITHKLINE-US2021142813:Same reporter US-GLAXOSMITHKLINE-US2021142815:Same reporter
Hives across  face , back and legs. Hives lasted  days.; This is a spontaneous report from a contactable other health care professional. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: en6199), via an intramuscular route in the left arm on 12Mar2021 at 13:00 (at the age of 49-years-old), as a single dose for COVID-19 Immunisation. Medical history included hypertension, reflux and allergies. Concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 12Mar2021, about 30 mins after the vaccination, the patient had hives across her face, back and legs. It was reported that hives lasted for many days. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of hives across face, back and legs were recovered on an unspecified date in Mar2021.  No follow-up attempts are needed. No further information is expected.
I had my vaccination on 10/07/2022. On 02/12/2023 I had a fever of 104. On 02/13/2023 I tested COVID-19 Positive. On 02/14/2023 I had a telehealth appointment. I was prescribed Paxlovid. I still suffer from shortness of breath. It was constant at the beginning of COVID it had tapered off but still present.
Within about an hour developed a severe headache and a temp to 104. Within 2 hours developed a rash on legs (more bumps than welts, but not tiny bumps - medium sized) and started itching all over body. Took Benadryl and Tylenol. Better by later the next day. Follow up - Adverse event date provided.
Almost 5-year-old on Clindemycin D7 for strep pharyngitis, received MMR/DTaP/IPV on 04/30/2003.  Rash on 05/01/2003 started neck-wide spread mamlopapular blanching.  Has arunete blanching lesions at all 3 injection sites.
Shortness of breath, flu like symptoms, chills, extreme fatigue, hot cold flashes, headaches, body aches, chest & neck pain, congestion
This spontaneous report was received from a pharmacist refers to a 73 year old patient of unknown gender. On 28-SEP-2012, the patient was vaccinated with a dose of PNEUMOVAX 23 (lot number was reported as 0595AA expiration date 30-AUG-2012). Concomitant medications were not reported. The reporter stated that the patient received PNEUMOVAX 23 on 28-SEP-2012 that had expired on 30-AUG-2012. The patient did not have a prior history of vaccination with PNEUMOVAX 23. No adverse event was reported. This is one of the several reports received from the same reporter. Additional information has been requested.
Pt had 2 doses of VARIVAX. 2wks after mother developed Shingles. She developed apparent post vaccination varicella. Titre at time of outbreak = 300.
swelling in arm with large red rash plus itching.  After one day the rash  spread down my arm to my elbow and felt hot.
The evening following my injection (Tuesday), I began to notice some mild redness and warmth around the injection site. The following day (Wednesday), the area had grown in size and color and my skin was getting harder and warmer. It was very sensitive to touch, but not itchy. The following day (Thursday) the spot began to spread out farther and was flattening, but was very warm to the touch and painful and my skin was hard still.  I took a benadryl Thursday afternoon and was taking ibuprofen every 6-8 or so hours since the injection for the pain and other mild symptoms I was experiencing. Today (Saturday) it is mostly flat, the redness has reduced and the pain is the lowest I've experienced. I did not have any of these symptoms with my first vaccine dose.  I took pictures every day to monitor, if that would be helpful.
30 min after getting shot mouth began itchy and runny nose.  Woke up next day terrible body aches and had trouble breathing.  Bad cough also.  Took Benadryl, Zyrtec, Advil.
pt recv vax 4SEP96 & exp sl discomfort in lt arm 4&5SEP-worse on 6SEP96;t101.2 in PM & area of edema & erythema egg sized;9SEP96 lt deltoid area still sl erythemic, painful;11SEP96 some ecchymosis but pt recovering;
My symptoms started almost 12 hours later.   Awful chills, aches, and incredible fatigue followed by a headache I could not shake.  It took me 2 full days to recuperate.  This 48 hours was horrible.
Extreme sore throat, deep lung congestion, nodules on lower lung filled with mucus (seen on X-ray and CT scan), fever over 100F, complete lethargy and lack of stamina (very unusual for me), lack of appetite, lack of interest in anything, cramps, muscle aches, headache (unusual for me) and inability to focus.
fatigue; HEADACHE; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nausea), FATIGUE (fatigue) and HEADACHE (HEADACHE) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No adverse event reported).   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Jan-2021, the patient experienced NAUSEA (Nausea) and HEADACHE (HEADACHE). On 23-Jan-2021, the patient experienced FATIGUE (fatigue). At the time of the report, NAUSEA (Nausea), FATIGUE (fatigue) and HEADACHE (HEADACHE) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
Swollen underarm; severe pain in underarm; disoriented; temperature for over 24 hours; chills; fatigue; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 13:30 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported.  The patient received unspecified medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Mar2021 at 09:00 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 02:15, the patient experienced swollen underarm, severe pain in underarm, disoriented, temperature for over 24 hours, chills and fatigue. On 14Apr2021, the patient underwent Body temperature and the result was unknown. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the events swollen underarm, severe pain in underarm, disoriented, temperature for over 24 hours, chills and fatigue was not resolved.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
This case was reported by a physician and described the occurrence of injection site redness in a 4 year old female subject who was vaccinated with diphtheria and tetanus toxoids and acellular pertussis vaccine absorbed (Infanrix) for prophylaxis. The subject had no pre existing medical conditions. There were no concurrent medications. On 3/22/2006, the subject received 5th dose of Infanrix in the left arm (lot AC14B018AA). On 3/22/2006, the subject also received the 4th dose of inactivated poliomyelitis virus vaccine (Ipol, lot Y0241) at an unspecified site of administration. On 3/22/2006, the same day as the vaccination with Infanrix, the subject experienced injection site redness, hardening injection site and heat at injection site at the site of the Infanrix administration. The subject was treated with Ibuprofen Advil and compresses. The physician considered who events to be disabling. The events resolved on an unspecified date on or after 3/22/2005 and on or before 5/11/2006.
A 29 year old female experienced generalized muscle aches, tiredness, headaches, sweating, chills and swollen lymph glands of 1/27/01, following vaccination with RabAvert for pre-exposure prophylaxis for potential future exposure to rabid animals at work. The subject received her 1st dose of RabAvert without experiencing any significant adverse events on 1/19/01. Twelve hours after the 2nd RabAvert vaccination on 1/26/01 at 03:00 AM, the pt experienced generalized muscle aches, feeling tired, headaches, sweating and chills. She also experienced swollen lymph glands in the axillary area of the arm that received the RabAvert injection. The subject received the 3rd RabAvert vaccination on 2/9/01. She recovered from the adverse events.
body ache; felt very cold and very hot; Joint pain; fever 37.5C; chills; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (body ache), FEELING OF BODY TEMPERATURE CHANGE (felt very cold and very hot), ARTHRALGIA (Joint pain), PYREXIA (fever 37.5C) and CHILLS (chills) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, the patient experienced PAIN (body ache), FEELING OF BODY TEMPERATURE CHANGE (felt very cold and very hot), ARTHRALGIA (Joint pain), PYREXIA (fever 37.5C) and CHILLS (chills). At the time of the report, PAIN (body ache), FEELING OF BODY TEMPERATURE CHANGE (felt very cold and very hot), ARTHRALGIA (Joint pain), PYREXIA (fever 37.5C) and CHILLS (chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Fever, chills, severe lower back ache and upper leg pain. Body aches. Heart palpitations, high heart rate. Headache. Lasted 3 days. Headache is still happening 6 days out and upper leg pain. Stomach ache started 4/11/21 and lasting
Fever 100.5 F., back pains, body aches, heart palpitations, and migraine.
Normal signs and symptoms at first, little hot and cold at first within the first 12 hours. 1/27...5 days post vaccine I was really tired before going into work and overnight it became more noticeable the pressure on my chest, difficulty breathing in deeply without pain in the center of my chest and a sore throat by the end of my shift.  Now approx 18 hrs from the initial onset  it hurts my chest when I swallow  and it passes through my esophagus. I?m really apprehensive about taking the other shot.
chicken pox increasing pox x 4 days then scabbed over;vaccine not effective in prev illness;;
Patient received Moderna vaccine 3/2/2021 0.5 ml LD IM Lot: 029L20A and Moderna vaccine 3/30/2021 0.5 ml LD IM Lot: 019B21A. The patient was exposed to an infected person with Covid about 1 week after her second vaccine. She was admitted to the ICU with severe covid on 4/13/21. She was eventually transitioned to comfort care and died on 5/6/2021.
she typically has a low WBC; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 69 year-old female patient received bnt162b2 (BNT162B2), administration date 27Aug2021 (Lot number: FC3184, Expiration Date: 31Oct2021) at the age of 68 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Pre-diabetic" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot FA7485, NDC unknown, expiration date 31Oct2021), administration date: 04Aug2021, when the patient was 68 years old, for COVID-19 Immunization. The following information was reported: WHITE BLOOD CELL COUNT DECREASED (non-serious), outcome "unknown", described as "she typically has a low WBC". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: The caller had called about the Pfizer Biontech vaccine. The caller had the first shot which was no issue. The caller had the second dose and she had a reaction. The caller was glad to have a reaction because she typically has a low WBC.  No follow-up attempts are possible. No further information is expected.
mom states crying started around 8PM & cont uninterrupted until 1AM 1MAR94; seen in ER t104 no other sx; MD advised family to cont fever rx; vomiting x 1;
COVID-19; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of COVID-19 (COVID-19) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with ACETYLSALICYLIC ACID, CAFFEINE, PARACETAMOL (CITRAMAX FORTE) for COVID-19, at a dose of UNK dosage form; ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for COVID-19, at a dose of UNK dosage form and ANTIBIOTICS for COVID-19, at a dose of UNK dosage form. At the time of the report, COVID-19 (COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 antibody test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medications reported.  Patient was treated with isolation as well.   This case was linked to US-MODERNATX, INC.-MOD-2021-065849, US-MODERNATX, INC.-MOD-2021-014845 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-065849:Reporter's co-worker wife case (female patient) US-MODERNATX, INC.-MOD-2021-014845:Reporter's case, female patient
Information has been received from a nurse practitioner and the patient's mother referring to a 13 years old female with none medical history, concomitant therapies and drug or allergy reactions. On 19-JAN-2018, the patient recieved the first dose of GARDASIL 9 (strength, dose, frequency, lot # and expiration date were not reported) intramuscularly for prophylaxis. On 22-AUG-2018, the patient recieved another dose of GARDASIL 9 (strength, dose, frequency were not reported) (lot number N032956, expiration date 13-JUL-2020) intramuscularly for prophylaxis. On 22-AUG-2018, an unspecified time after receiving the dose of GARDASIL 9, the patient developed "arm pain that radiated to the shoulder" and still persisted at the time of reported. There was no lab diagnostics, studies performed or treatment given. It was reported the therapy was not discontinued. Causality assessment was not provided.
Patient reported complete bilateral hearing loss several days after receiving flu vaccine. Vaccine was given 9/12/11. Patient reported hearing loss on 9/19/11 that started on 9/17/11.
Swelling under left armpit, fever, chills, muscle aches, stomach pain and cramping.
After receiving my First Dose of Moderna Vaccine I developed a rash & hives over my entire body. I went to the local hospital ER and was treated with appropriate medications. After 4-5 hours I was sent home with prescriptions.
This spontaneous report as received from a physician refers to a female friend of his wife of unknown age with hypothyroidism. The patient was vaccinated with ZOSTAVAX (Lot# unspecified) on an unknown date. No other co-suspects were reported. No concomitant medications were reported. On an unknown date the patient experienced balance disturbance. The patient had an evaluation with her primary care physician and it was felt the balance disturbance was related to her hypothyroidism. The patient was treated with a course of steroid medication and the symptoms resolved. The patient had sought medical attention via office visit. Additional information is not expected.
Severe headache. Headache moved to different parts of the head and face, including sinus area, jaw, and top of the head; severe aches; fatigue; fever; chills; This is a spontaneous report from a non- contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 18May2021 at 15:00 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS), GERD, seasonal allergy and vestibular disorder (vestibular weakness). Patient previously took bactrim and nitrofurantoin on an unknown date for unknown indication and experienced drug allergy. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 for (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 27Apr2021 at 15:30 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18May2021 at 18:00, the patient experienced Severe headache that did not respond to treatment and lasted more than 48 hours. Headache moved to different parts of the head and face, including sinus area, jaw, and top of the head. Accompanied by severe aches, fatigue, fever, chills. Therapeutic measures were taken for the reported event of severe headache and treatment was not specified. No therapeutic measures were taken for the events of severe aches, fever, fatigue and chills. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event of severe headache, headache moved to different parts of the head and face, including sinus area, jaw, and top of the head, severe aches, fatigue, fever and chills were not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.